Prognostic value and therapeutic response of neutrophil-to-lymphocyte ratio in penile cancer.

Authors

Xingliang Tan

Xingliang Tan

Department of Urology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center of Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, Guangdong, China

Xingliang Tan , Yiqi Yu , Hang Li , Weicheng Wu , Juexiao Chen , Zhiming Wu , Kai Yao

Organizations

Department of Urology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center of Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, Guangdong, China, Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, China, Sun Yat-sen University Cancer Center, Guangzhou, China, Department of Urology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center of Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China

Research Funding

Natural Science Foundation of Guangdong Province, China

Background: Chronic inflammation mediated by poor genital hygiene is a well-recognized pathogenic trigger for penile squamous cell carcinoma (PSCC). The neutrophil-to-lymphocyte ratio (NLR) is a simple and reproducible factor reflecting the systemic inflammatory response and has been reported as an unfavorable indicator in PSCC. However, previous studies limited by small sample sizes, confounding prognostic features and without high-quality evidence to demonstrate the clinical significance of the NLR. Methods: A large cohort of 582 penile cancer patients who underwent radical inguinal lymphadenectomy with definitive pN stages were enrolled in this study. Univariate and multivariate Cox regression analyses were performed to investigate prognostic factors and inflammation-related markers in PSCC patients. More importantly, the propensity score matching (PSM) method was used to minimize the prognostic confounding clinicopathological features. Immunofluorescence was further used to investigate the correlation between tumor-infiltrating neutrophils, CD8+ T cells and the NLR. Results: According to the ROC curve, the optimal cutoff value for the NLR was 3.0, and 226 (38.8%) PSCC patients had a high NLR. Survival analyses indicated that advanced pT, pN, pathological grade, lymphovascular invasion, high NLR, C-reactive protein (≥ 2.2 mg/L) and serum amyloid A (≥ 11.3 mg/L) were associated with poor PFS and CSS. After PSM to eliminate interference from clinical factors, pN and the NLR were found to be independent prognostic indicators in PSCC patients (both p<0.001). Cox multivariate regression analysis revealed that the HR for PFS was 1.64 (1.15–2.34) in the high NLR group and 1.56 (1.04–2.34) in the high NLR group (p=0.006 and 0.030, respectively). PSCC patients with high NLRs experienced shorter PFS after receiving cisplatin-based chemotherapy (p=0.037) and PD-1 immunotherapy (p=0.020). In addition, we found that the infiltration of tumor-associated neutrophils (CD66+) and the CD8+ T-cell ratio were positively correlated with the NLR. The development and formation of neutrophil extracellular traps (NETs) might contribute to chemoresistance and tumor progression in high-NLR PSCC patients. Conclusions: In this study, we demonstrated that the NLR is an effective, simple and independent prognostic indicator for PSCC. The NLR holds promise as a powerful tool to guide decision-making in clinical practice.

Univariate and multivariate analysis of clinicopathological factors associated with survival after PSM.

PFS after PSMCSS after PSM
Univariate analysisMultivariate analysisUnivariate analysisMultivariate analysis
VariablesHRP-valueHRP-valueHRP-valueHRP-value
Age
(>55 vs ≤55)
0.85 (0.60 - 1.19)0.3501.21 (0.85 - 1.73)0.2830.95 (0.64 - 1.40)0.7901.42 (0.95 - 2.13)0.087
BMI
(>23 vs ≤23)
1.03 (0.92 - 1.14)0.6401.09 (0.97 - 1.23)0.1521.03 (0.93 - 1.15)0.5641.11 (0.98 - 1.25)0.087
pT stage1.17 (1.07 - 1.27)<0.0011.12 (0.95 - 1.31)0.1791.14 (1.03 - 1.26)0.0131.07 (0.89 - 1.28)0.495
pN stage2.22 (1.90 - 2.58)<0.0012.22 (1.89 - 2.60)<0.0012.22 (1.86 - 2.65)<0.0012.28 (1.89 - 2.75)<0.001
Pathological grade1.13 (1.04 - 1.24)0.0060.99 (0.85 - 1.17)0.9291.10 (0.99 - 1.23)0.0840.97 (0.81 - 1.17)0.759
LVI/PNI
(Yes vs No)
1.55 (1.06 - 2.27)0.0231.12 (0.76 - 1.66)0.5621.66 (1.09 - 2.55)0.0191.25 (0.81 - 1.94)0.320
NLR
(≥3.0 vs <3.0)
1.81 (1.27 - 2.56)<0.0011.64 (1.15 - 2.34)0.0061.81 (1.21 - 2.69)0.0041.56 (1.04 - 2.34)0.030

PSM: propensity score matching; CSS: cancer specific survival; HR: hazard ratio; 95% Cl: 95% confidence interval; LVI: lymphovascular invasion; PNI: perineural invasion; NLR: neutrophil-lymphocyte ratio.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2024 ASCO Breakthrough

Session Type

Poster Session

Session Title

Poster Session A

Track

Gastrointestinal Cancer,Central Nervous System Tumors,Developmental Therapeutics,Genitourinary Cancer,Quality of Care,Healthcare Equity and Access to Care,Population Health,Viral-Mediated Malignancies

Sub Track

Novel preclinical models

Citation

J Clin Oncol 42, 2024 (suppl 23; abstr 116)

DOI

10.1200/JCO.2024.42.23_suppl.116

Abstract #

116

Poster Bd #

H6

Abstract Disclosures